Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P38398: Variant p.Arg1347Gly

Breast cancer type 1 susceptibility protein
Gene: BRCA1
Feedback?
Variant information Variant position: help 1347 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Glycine (G) at position 1347 (R1347G, p.Arg1347Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism: help There is evidence that the presence of the rare form of Gln-356-Arg and Leu-871-Pro polymorphisms may be associated with an increased risk for developing ovarian cancer. Additional information on the polymorphism described.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1347 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1863 The length of the canonical sequence.
Location on the sequence: help QSESQGVGLSDKELVSDDEE R GTGLEENNQEEQSMDSNLGE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         QSESQGVGLSDKELVS-DDEERGTGLEENN-QEEQSMDSNLGE

Gorilla                       QSESQGVGLSDKELVS-DDEERGTGLEENN-QEEQSMDSNL

                              QSENLDV-LNDKELVSDDDDEREPGLEEDSPQEEQSVDSDL

Rhesus macaque                QSESQGVGLSDKELVS-DDEERGTGLEEDN-QEEQSVDSNL

Chimpanzee                    QSESQGVGLSDKELVS-DDEERGTGLEENN-QEEQSMDSNL

Mouse                         QCGNEEAFLSDKELIS-DNEEMATCLEEDNDQEEDSIIPD-

Rat                           QAENEEAFLSDKELIS-DHEDMAACLEEASDQEEDSIIPD-

Bovine                        QSESEEV-LSDKELVS-DDEERETGLEEDSCQEEQSVDSDL

Caenorhabditis elegans        --------ASDDDEVV-EDSEGELQIDEDD-----------

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1863 Breast cancer type 1 susceptibility protein
Region 1322 – 1387 Disordered
Compositional bias 1338 – 1353 Basic and acidic residues
Modified residue 1328 – 1328 Phosphoserine
Modified residue 1336 – 1336 Phosphoserine
Modified residue 1342 – 1342 Phosphoserine
Alternative sequence 64 – 1863 Missing. In isoform 2.
Alternative sequence 224 – 1365 Missing. In isoform 5.
Alternative sequence 264 – 1366 Missing. In isoform 3 and isoform 6.
Mutagenesis 1330 – 1330 S -> A. No effect on in vitro phosphorylation by ATR.



Literature citations
Characterization of common BRCA1 and BRCA2 variants.
Deffenbaugh A.M.; Frank T.S.; Hoffman M.; Cannon-Albright L.; Neuhausen S.L.;
Genet. Test. 6:119-121(2002)
Cited for: VARIANTS GLY-1347; ILE-1512 AND ILE-1652;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.